Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27585728 | 0.98 | ATM (0.41) | ATMBCL2NPC1RAB9A | |
| SCHEMBL5894589 | 0.71 | — | — | |
| SCHEMBL9531 | 0.69 | ATM (0.48) | ATM | |
| SCHEMBL5894528 | 0.67 | KDM4E (0.35) | NPC1RAB9A | |
| SCHEMBL5894144 | 0.67 | MMP2 (0.35) | NPC1RAB9AALOX12 | |
| SCHEMBL28126562 | 0.67 | ATM (0.46) | ATM | |
| Hydrochloric Acid SCHEMBL7370284 | 0.67 | BCHE (0.50) | — | |
| Water SCHEMBL5786021 | 0.67 | ATM (0.46) | ATM | |
| SCHEMBL27684621 | 0.67 | ATM (0.46) | ATM | |
| Fluoride SCHEMBL27608168 | 0.67 | ATM (0.46) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742042-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2014-06-18 | — | — | EP | claimed |
| WO-2013021363-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-02-14 | — | — | WO | claimed |
| US-20060156485-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2006-07-20 | — | — | US | claimed |
| EP-2742042-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013021363-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-02-14 | — | — | WO | disclosed |
| US-20120129876-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120088736-A1 | [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| EP-2428514-A1 | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto | Portola Pharmaceuticals, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120009172-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| EP-1951254-B1 | [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO | PORTOLA PHARM INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8058284-B2 | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-4371685-A | Radiation-reactive precursor stages of highly heat-resistant polymers | SIEMENS AKTIENGESELLSCHAFT (DE) | 1983-02-01 | — | — | US | disclosed |
| US-4366230-A | Method for the preparation of highly heat-resistant relief structures and the use thereof | SIEMENS AKTIENGESELLSCHAFT (DE) | 1982-12-28 | — | — | US | disclosed |
| US-4332883-A | POLYAMIDE HAVING HYDROXYL GROUPS MODIFIED WITH GLYCIDYL ACRYLATE OR METHACRYLATE | SIEMENS AKTIENGESELLSCHAFT (DE) | 1982-06-01 | — | — | US | disclosed |
| US-4332882-A | POLYIMIDAZOLES AND POLYIMIDAZOPYRROLONES | SIEMENS AKTIENGESELLSCHAFT (DE) | 1982-06-01 | — | — | US | disclosed |
| US-4311785-A | Method for the preparation of highly heat-resistant relief structures and the use thereof | SIEMENS AKTIENGESELLSCHAFT (DE) | 1982-01-19 | — | — | US | disclosed |
| US-4258187-A | REACTING 2-AMINO-BENZOPHENONE DERIVATIVES WITH A HYDROXYLAMINE SALT | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-03-24 | — | — | US | disclosed |
| US-4160092-A | FOR 3-FLUOROBENZODIAZEPINES USEFUL AS SEDATIVES, TRANQUILIZERS AND MXUCLE RELAXANTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-07-03 | — | — | US | disclosed |
| EP-0000149-A1 | Process for preparing quinazolinone oxides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-01-10 | — | — | EP | disclosed |
| EP-0000148-A1 | Quinazolinone oxides and process for their preparation | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009172-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | P2RY12, P2RY11, P2RY13 | ATM 2244/4885BCL2 4660/4885NPC1 3834/4885 |
| US-20120088736-A1 | [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto | P2RX7, P2RY1, P2RY6 | ATM 4059/4885BCL2 4250/4885NPC1 1398/4885 |
| US-20060156485-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, TUBB6, DNMT1 | ATM 3130/4885BCL2 1827/4885NPC1 4475/4885 |
| US-20120129876-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | P2RY1, P2RY6, P2RY4 | ATM 4340/4885BCL2 4088/4885NPC1 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.